- Home
- VICI vs BIIB Comparison
VICI vs BIIB Comparison
Compare VICI & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VICI | BIIB |
|---|---|---|
| Founded | 2016 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.7B | 27.1B |
| IPO Year | 2017 | 1996 |
Fundamental Metrics
Financial Performance| Metric | VICI | BIIB |
|---|---|---|
| Price | $27.85 | $174.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 28 |
| Target Price | $34.00 | ★ $197.46 |
| AVG Volume (30 Days) | ★ 7.5M | 919.0K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ 1.95 | N/A |
| EPS | 2.61 | ★ 8.79 |
| Revenue | $4,006,116,000.00 | ★ $9,890,600,000.00 |
| Revenue This Year | $4.52 | N/A |
| Revenue Next Year | $1.48 | N/A |
| P/E Ratio | ★ $10.59 | $19.57 |
| Revenue Growth | ★ 4.08 | 2.22 |
| 52 Week Low | $26.55 | $110.04 |
| 52 Week High | $34.01 | $202.41 |
Technical Indicators
Market Signals| Indicator | VICI | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 40.57 |
| Support Level | $27.65 | $170.99 |
| Resistance Level | $28.75 | $188.76 |
| Average True Range (ATR) | 0.54 | 5.40 |
| MACD | 0.08 | -1.25 |
| Stochastic Oscillator | 65.85 | 26.74 |
Price Performance
Historical ComparisonAbout VICI VICI Properties Inc.
VICI Properties Inc is a real estate investment trust based in the United States. It engaged in the business of owning and acquiring gaming, hospitality, wellness, entertainment and leisure destinations, subject to long-term triple net leases. It own nearly 93 experiential assets across a geographically portfolio consisting of nearly 54 gaming properties and nearly 39 other experiential properties across the United States and Canada, including Caesars Palace Las Vegas, MGM Grand and the Venetian Resort Las Vegas.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).